Travis Steed
Stock Analyst at B of A Securities
(2.76)
# 1,697
Out of 5,182 analysts
93
Total ratings
45.07%
Success rate
6.04%
Average return
Main Sectors:
Stocks Rated by Travis Steed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MMED Minimed Group | Initiates: Buy | $27 | $13.23 | +104.08% | 1 | Mar 31, 2026 | |
| TNDM Tandem Diabetes Care | Upgrades: Neutral | $15 → $30 | $18.28 | +64.11% | 3 | Feb 20, 2026 | |
| BBNX Beta Bionics | Maintains: Buy | $30 → $33 | $9.73 | +239.16% | 1 | Jan 5, 2026 | |
| PEN Penumbra | Maintains: Buy | $320 → $370 | $329.96 | +12.13% | 2 | Jan 5, 2026 | |
| BDX Becton, Dickinson and Company | Maintains: Neutral | $190 → $207 | $154.96 | +33.58% | 10 | Jan 5, 2026 | |
| CNMD CONMED | Maintains: Neutral | $65 → $52 | $34.54 | +50.55% | 5 | Dec 8, 2025 | |
| MASI Masimo | Initiates: Neutral | $162 | $178.73 | -9.36% | 1 | Nov 17, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $133 → $150 | $101.83 | +47.30% | 5 | Mar 10, 2025 | |
| SOLV Solventum | Maintains: Neutral | $80 → $85 | $62.49 | +36.02% | 3 | Feb 26, 2025 | |
| EW Edwards Lifesciences | Upgrades: Buy | $82 → $90 | $80.84 | +11.33% | 4 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $17.88 | +78.97% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $42 → $45 | $16.62 | +170.76% | 5 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $480 → $45 | $4.10 | +997.56% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $315 | $332.07 | -5.14% | 5 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $365 → $295 | $202.46 | +45.71% | 3 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $30.99 | -48.37% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 → $160 | $91.40 | +75.05% | 11 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $315 | $452.95 | -30.46% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $8 | $1.28 | +525.00% | 1 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $25 | $8.83 | +183.13% | 1 | Jun 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $85 | $13.65 | +522.71% | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $63.11 | +98.07% | 7 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $145 | $86.42 | +67.79% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $51 | $61.86 | -17.56% | 9 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $59 → $54 | $9.33 | +478.78% | 2 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $78.08 | -71.82% | 1 | Jul 17, 2017 |
Minimed Group
Mar 31, 2026
Initiates: Buy
Price Target: $27
Current: $13.23
Upside: +104.08%
Tandem Diabetes Care
Feb 20, 2026
Upgrades: Neutral
Price Target: $15 → $30
Current: $18.28
Upside: +64.11%
Beta Bionics
Jan 5, 2026
Maintains: Buy
Price Target: $30 → $33
Current: $9.73
Upside: +239.16%
Penumbra
Jan 5, 2026
Maintains: Buy
Price Target: $320 → $370
Current: $329.96
Upside: +12.13%
Becton, Dickinson and Company
Jan 5, 2026
Maintains: Neutral
Price Target: $190 → $207
Current: $154.96
Upside: +33.58%
CONMED
Dec 8, 2025
Maintains: Neutral
Price Target: $65 → $52
Current: $34.54
Upside: +50.55%
Masimo
Nov 17, 2025
Initiates: Neutral
Price Target: $162
Current: $178.73
Upside: -9.36%
Abbott Laboratories
Mar 10, 2025
Maintains: Buy
Price Target: $133 → $150
Current: $101.83
Upside: +47.30%
Solventum
Feb 26, 2025
Maintains: Neutral
Price Target: $80 → $85
Current: $62.49
Upside: +36.02%
Edwards Lifesciences
Dec 16, 2024
Upgrades: Buy
Price Target: $82 → $90
Current: $80.84
Upside: +11.33%
Nov 5, 2024
Initiates: Buy
Price Target: $32
Current: $17.88
Upside: +78.97%
Mar 5, 2024
Maintains: Neutral
Price Target: $42 → $45
Current: $16.62
Upside: +170.76%
Oct 13, 2023
Downgrades: Underperform
Price Target: $480 → $45
Current: $4.10
Upside: +997.56%
Sep 5, 2023
Upgrades: Buy
Price Target: $315
Current: $332.07
Upside: -5.14%
Aug 24, 2023
Maintains: Buy
Price Target: $365 → $295
Current: $202.46
Upside: +45.71%
Aug 22, 2023
Reiterates: Overweight
Price Target: $16
Current: $30.99
Upside: -48.37%
May 3, 2023
Upgrades: Neutral
Price Target: $120 → $160
Current: $91.40
Upside: +75.05%
Apr 19, 2023
Maintains: Buy
Price Target: $300 → $315
Current: $452.95
Upside: -30.46%
Jan 3, 2023
Downgrades: Underperform
Price Target: $8
Current: $1.28
Upside: +525.00%
Jun 21, 2022
Initiates: Underperform
Price Target: $25
Current: $8.83
Upside: +183.13%
Oct 13, 2021
Maintains: Overweight
Price Target: $120 → $85
Current: $13.65
Upside: +522.71%
May 25, 2021
Initiates: Overweight
Price Target: $125
Current: $63.11
Upside: +98.07%
May 25, 2021
Initiates: Equal-Weight
Price Target: $145
Current: $86.42
Upside: +67.79%
May 25, 2021
Initiates: Overweight
Price Target: $51
Current: $61.86
Upside: -17.56%
Nov 1, 2018
Maintains: Neutral
Price Target: $59 → $54
Current: $9.33
Upside: +478.78%
Jul 17, 2017
Initiates: Overweight
Price Target: $22
Current: $78.08
Upside: -71.82%